Related references
Note: Only part of the references are listed.SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among US Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis
Evan J. Anderson et al.
AMERICAN JOURNAL OF PERINATOLOGY (2020)
Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants
Leonard R. Krilov et al.
AMERICAN JOURNAL OF PERINATOLOGY (2020)
Respiratory Syncytial Virus Hospitalizations among US Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016
Mitchell Goldstein et al.
AMERICAN JOURNAL OF PERINATOLOGY (2018)
Respiratory Syncytial Virus Seasonality - United States, 2014-2017
Erica Billig Rose et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
Valeria Belleudi et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2018)
The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
Amanda M. Kong et al.
AMERICAN JOURNAL OF PERINATOLOGY (2018)
SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among US Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis
Evan J. Anderson et al.
AMERICAN JOURNAL OF PERINATOLOGY (2017)
Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience
Bavani Rajah et al.
JOURNAL OF PEDIATRICS (2017)
Effectiveness of Palivizumab in High-risk Infants and Children A Propensity Score Weighted Regression Analysis
Evan J. Anderson et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)
The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
Antonino Capizzi et al.
ITALIAN JOURNAL OF PEDIATRICS (2017)
Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: is there still room for debating?
Gianvincenzo Zuccotti et al.
ITALIAN JOURNAL OF PEDIATRICS (2017)
Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
Carlina J. Grindeland et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)
Zbynek Stranak et al.
PLOS ONE (2016)
Methods for Evaluating Changes in Health Care Policy The Difference-in-Differences Approach
Justin B. Dimick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis
Shawn L. Ralston et al.
PEDIATRICS (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Policy Statement-Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
Joseph A. Bocchini et al.
PEDIATRICS (2009)
Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics
Giovanni A. Rossi et al.
EUROPEAN JOURNAL OF PEDIATRICS (2007)
Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000
S Leader et al.
JOURNAL OF PEDIATRICS (2003)
Medical progress - Respiratory syncytial virus and parainfluenza virus.
CB Hall
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid
TG Boyce et al.
JOURNAL OF PEDIATRICS (2000)
Share Paper
